Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen

Zusammenfassung

Die derzeitige Standardtherapie bei Kindern und Jugendlichen mit neu diagnostizierter Langerhanszell Histiozytose (LCH) beruht auf den Medikamenten Prednison und Vinblastin. Im Falle eines schlechten Therapieansprechens bzw. Reaktivierung hängt das weitere Vorgehen von Faktoren wie zum Beispiel des Befalls eines Risikoorgans wie Leber, Milz oder hämatopoetisches System ab. Der folgende Artikel gibt eine Übersicht über die wichtigsten aktuellen Daten zu Therapieoptionen in den unterschiedlichen klinischen Situationen, die aufgrund der fehlenden Evidenz meist nicht ausführlich in den aktualisierten Leitlinien dargestellt werden. Auch werden neue Therapieoptionen wie Inhibitoren des MAP-Kinase Signalweges diskutiert. Falls diese Therapiestrategien in Erwägung gezogen werden, sollte dies mit dem zuständigen Referenzzentrum diskutiert werden. Zudem sollten alle Kinder und Jugendliche mit LCH in laufende Register oder Studien eingeschlossen werden.

Abstract

The current standard therapy for children and adolescents with newly diagnosed Langerhans cell histiocytosis (LCH) is based on the two drugs prednisone and vinblastine. In patients with insufficient treatment response or disease relapse, the choice of second-line treatment depends on risk organ involvement (liver, spleen, and hematopoietic system). This article will give an overview of current data concerning therapeutic options in the different settings of children and adolescents with LCH. Due to limited evidence, these strategies have not been described in detail in the updated guidelines on pediatric LCH. In addition, the use of targeted therapy such as MAP-kinase inhibitors will be discussed. The reference center for LCH should be contacted if therapeutic options beyond the standard regimen are considered for treatment. All children and adolescents with LCH should be enrolled in registries or prospective studies.

Schlüsselwörter

Langerhanszell Histiozytose - Kind - Therapiestrategie - Stamzelltransplantation - zielgerichtete Therapie

Key words

Langerhans cell histiocytosis - child - therapeutic options - hematopoietic cell transplantation - targeted therapy

Publication History

Article published online:
06 September 2023

• Literatur

• 1 Lehrnbecher T, Ahlmann M, Albert MH. et al. Aktualisierte AWMF Leitlinie zur Diagnostik und Therapie der Langerhanszell Histiozytose (LCH) im Kindes- und Jugendalter. Klin Padiatr (im Druck)..
• 2 Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). S1-Leitlinie Langerhanszell-Histiozytose (LCH) im Kindes- und Jugendalter. Version 8.0 (Stand 30.4.2023). AWMF online: https://register.awmf.org/assets/guidelines/025-015l_S1_Langerhanszell-Histiozytose-LCH-Kinder-Jugendliche_2023-05.pdf [aufgerufen 21. Juni, 2023].
• 3 Gadner H, Heitger A, Grois N. et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994; 23: 72-80
• 4 Minkov M, Grois N, Heitger A. et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 2000; 212: 139-144
• 5 Gadner H, Grois N, Arico M. et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728-734
• 6 Gadner H, Grois N, Potschger U. et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008; 111: 2556-2562
• 7 Gadner H, Minkov M, Grois N. et al. Therapy prolongation improves outcome in multi-system Langerhans cell histiocytosis. Blood. 2013; 121: 5006-5014
• 8 Grois N, Potschger U, Prosch H. et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228-233
• 9 Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol 1993; 21: 265-270
• 10 De Benedittis D, Mohamed S, Rizzo L. et al. Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH). Br J Haematol 2020; 191: e109-e113
• 11 Elomaa I, Blomqvist C, Porkka L. et al. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med 1989; 225: 59-61
• 12 Chellapandian D, Makras P, Kaltsas G. et al. Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. Mediterr J Hematol Infect Dis 2016; 8: e2016033
• 13 Kudo K, Tanaka T, Kobayashi A. et al. Zoledronic acid for relapsed Langerhans cell histiocytosis with isolated skull bone lesion. Pediatr Int 2019; 61: 315-317
• 14 Morimoto A, Shioda Y, Imamura T. et al. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2011; 56: 110-115
• 15 Arico M, Colella R, Conter V. et al. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med Pediatr Oncol 1995; 25: 12-16
• 16 Minkov M, Grois N, Broadbent V. et al. Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol 1999; 33: 482-485
• 17 Culic S, Jakobson A, Culic V. et al. Etoposide as the basic and interferon-alpha as the maintenance therapy for Langerhans cell histiocytosis: a RTC. Pediatr Hematol Oncol 2001; 18: 291-294
• 18 Barkaoui MA, Queheille E, Aladjidi N. et al. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br J Haematol 2020; 191: 825-834
• 19 Weitzman S, Braier J, Donadieu J. et al. 2’-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society. Pediatr Blood Cancer 2009; 53: 1271-1276
• 20 Irie M, Nakano T, Katayama S. et al. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis. Cancer Rep (Hoboken) 2022; 5: e1579
• 21 Bernard F, Thomas C, Bertrand Y. et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682-2689
• 22 Donadieu J, Bernard F, van Noesel M. et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015; 126: 1415-1423
• 23 Simko SJ, Tran HD, Jones J. et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 2014; 61: 479-487
• 24 Kudo K, Maeda M, Suzuki N. et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. Int J Hematol 2020; 111: 137-148
• 25 Veys PA, Nanduri V, Baker KS. et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol 2015; 169: 711-718
• 26 Heritier S, Emile JF, Helias-Rodzewicz Z. et al. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Arch Pediatr 2019; 26: 301-307
• 27 Pearson AD, Allen C, Fangusaro J. et al. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022; 177: 120-142
• 28 Donadieu J, Larabi IA, Tardieu M. et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol 2019; 37: 2857-2865
• 29 Evseev D, Kalinina I, Raykina E. et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Int J Hematol 2021; 114: 725-734
• 30 Yang Y, Wang D, Cui L. et al. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis. Cancer Res Treat 2021; 53: 261-269
• 31 Eckstein OS, Visser J, Rodriguez-Galindo C. et al. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019; 133: 1691-1694
• 32 Imashuku S, Fujita N, Shioda Y. et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol 2015; 101: 191-197
• 33 Allen CE, Flores R, Rauch R. et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer 2010; 54: 416-423
• 34 Cohen Aubart F, Idbaih A, Emile JF. et al. Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro Oncol 2021; 23: 1433-1446
• 35 Henter JI, Kvedaraite E, Martin Munoz D. et al. Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. Br J Haematol 2022; 196: 248-254